Single cell and bulk RNA expression analyses identify enhanced hexosamine biosynthetic pathway and O-GlcNAcylation in acute myeloid leukemia blasts and stem …
R Schauner, J Cress, C Hong, D Wald… - Frontiers in …, 2024 - frontiersin.org
Introduction Acute myeloid leukemia (AML) is the most common acute leukemia in adults
with an overall poor prognosis and high relapse rate. Multiple factors including genetic …
with an overall poor prognosis and high relapse rate. Multiple factors including genetic …
Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations
X Zheng, Z Chen, M Guo, H Liang, X Song… - ACS Pharmacology & …, 2024 - ACS Publications
Secondary mutations in Fms-like tyrosine kinase 3-tyrosine kinase domain (FLT3-TKD)(eg,
D835Y and F691L) have become a major on-target resistance mechanism of FLT3 …
D835Y and F691L) have become a major on-target resistance mechanism of FLT3 …
Red blood cell membrane-coated FLT3 inhibitor nanoparticles to enhance FLT3-ITD acute myeloid leukemia treatment
J Liu, J Chen, X Zhang, Y Wu, X Qi, J Wang… - Chinese Chemical …, 2024 - Elsevier
FMS-like tyrosine kinase 3 (FLT3) is a viable and important therapeutic target for acute
myeloid leukemia (AML). FLT3 internal tandem duplication (FLT3-ITD) mutations have been …
myeloid leukemia (AML). FLT3 internal tandem duplication (FLT3-ITD) mutations have been …